Drug Trial Radar · NCT00556374
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,420
Actual
Start
Dec 18, 2006
Primary completion
Oct 7, 2014
Study completion Jul 26, 2022
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- Collaborators
- Austrian Breast & Colorectal Cancer Study Group
- First posted
- Nov 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- Who can join
- Female only, from 45 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.
Conditions
- Breast Cancer
Interventions
PlaceboDrug
DenosumabBiological
Administered as a subcutaneous injection
Non-steroidal aromatase inhibitor therapyDrug
An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
Zoledronic AcidDrug
5 mg zoledronic acid administered at a constant infusion rate
Standard of CareOther
Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Clinical FractureTime frame: From randomization until the primary analysis cut-off date of 26 March 2014; maximum time on main study at the cut-off was 87 months
Locations
46 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Baden, Austria
Research Site
Braunau am Inn, Austria
Research Site
Dornbirn, Austria
Research Site
Feldkirch, Austria
Research Site
Gmunden, Austria
Research Site
Graz, Austria
Research Site
Graz, Austria
Research Site
Guessing, Austria
Research Site
Hall in Tirol, Austria
Research Site
Innsbruck, Austria
Research Site
Klagenfurt, Austria
Research Site
Krems, Austria
Research Site
Kufstein, Austria
Research Site
Leoben, Austria
Research Site
Lienz, Austria
Research Site
Linz, Austria
Research Site
Linz, Austria
Research Site
Oberpullendorf, Austria
Research Site
Ried, Austria
Research Site
Rottenmann, Austria
Research Site
Salzburg, Austria
Research Site
Sankt Pölten, Austria
Research Site
Sankt Veit an der Glan, Austria
Research Site
Schaerding, Austria
Research Site
Steyr, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Villach, Austria
Research Site
Villach, Austria
Research Site
Vöcklabruck, Austria
Research Site
Weiz, Austria
Research Site
Wels, Austria
Research Site
Wiener Neustadt, Austria
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.